Surrozen (SRZN) Cash from Investing Activities (2020 - 2026)
Surrozen (SRZN) recorded quarterly Cash from Investing Activities of -$120000.0 in Q1 2026, down 103.39% quarter-over-quarter from -$59000.0 in Q4 2025, and down 344.44% on a YoY basis from $49090.9 in Q1 2025.
Surrozen (SRZN) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Surrozen's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$120000.0 for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 344.44% year-over-year to -$120000.0; the TTM figure through Mar 2026 stood at -$221000.0 (down 380.43% YoY), while the FY2025 annual figure was -$128000.0, down 392.31% from the prior year.
- Cash from Investing Activities was -$120000.0 for Q1 2026 at Surrozen, down from -$59000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $22.8 million in Q3 2022 to a low of -$412000.0 in Q1 2022.
- Historically, Cash from Investing Activities has averaged $6.0 million across 5 years, with a median of -$7000.0 in 2024.
- The sharpest annual moves came in 2023 and 2026: Cash from Investing Activities surged 4305.83% in 2023, then slumped 344.44% in 2026.
- A 5-year view of Cash from Investing Activities shows it stood at $1.9 million in 2022, then soared by 396.6% to $9.5 million in 2023, then tumbled by 100.2% to -$19000.0 in 2024, then sank by 210.53% to -$59000.0 in 2025, then sank by 103.39% to -$120000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$120000.0 (Q1 2026), -$59000.0 (Q4 2025), and -$24000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 579,519.10 |
| 10 | Surrozen | 239,016.67 | -106.67 Mn | - | -120,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -120,000.00 |
| Mar 31, 2026 | -120,000.00 |
| Dec 31, 2025 | -59,000.00 |
| Dec 31, 2025 | -59,000.00 |
| Sep 30, 2025 | -24,000.00 |
| Sep 30, 2025 | -24,000.00 |
| Jun 30, 2025 | -18,000.00 |
| Jun 30, 2025 | -18,000.00 |
| Mar 31, 2025 | -27,000.00 |
| Mar 31, 2025 | -27,000.00 |
| Dec 31, 2024 | -19,000.00 |
| Dec 31, 2024 | -19,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Dec 31, 2023 | 9.50 Mn |
| Dec 31, 2023 | 9.50 Mn |
| Sep 30, 2023 | 7.65 Mn |
| Sep 30, 2023 | 7.65 Mn |
| Jun 30, 2023 | 17.25 Mn |
| Jun 30, 2023 | 17.25 Mn |